SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Nabi (NABI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Extra Pale who wrote (284)9/21/2000 2:47:09 PM
From: Torben Noerup Nielsen   of 354
 
Consider a few things. First, what is the cost of a serious S. aureus infection in an immune compromised individual? Take half of that. Then multiply by 0.57 and by the number of patients involved. That would be my first cut at a gross sales figure.

Also consider that this vaccine may have bovine applications. In addition, a number of vaccines have to be given multiple times in order to confer full protection. Sometimes the interval is over a year.

I'm not all that concerned about the endpoints. But I would like to know if re-administration of the vaccine is effective. If it needs to be given every 3 months to immune compromised patients in order to be effective, so much the better for sales.

Also, this says nothing about how effective the vaccine might be in immunocompetent patients. Would it be useful for hospital personnel who are constantly at risk for nosocomic infections? If so, the market is much larger.

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News